Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

INTRODUCTION: The clinical outcomes of sequential treatment of advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs are unclear. Thus, we aimed to analyze the outcomes of these pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Huang, Chun-Yao, Lin, Yu-Ching, Lee, Suey-Haur, Chiu, Li-Chung, Wu, Chiao-En, Kuo, Scott Chih-Hsi, Ju, Jia-Shiuan, Huang, Allen Chung-Cheng, Ko, Ho-Wen, Wang, Chin-Chou, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579797/
https://www.ncbi.nlm.nih.gov/pubmed/37854677
http://dx.doi.org/10.3389/fonc.2023.1249106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579797/
https://www.ncbi.nlm.nih.gov/pubmed/37854677
http://dx.doi.org/10.3389/fonc.2023.1249106

Ejemplares similares